Brain-derived neurotrophic factor levels across psychiatric disorders: A systemic review and network meta-analysis
Yazhu Zou,Yuan Zhang,Mengtian Tu,Yu Ye,Mingmei Li,Rongting Ran,Zhili Zou
DOI: https://doi.org/10.1016/j.pnpbp.2024.110954
IF: 5.201
2024-01-29
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Abstract:As an important neurotrophic factor in the central nervous system, Brain-derived Neurotrophic Factor (BDNF) has been implicated in the pathophysiology of psychiatric disorders in many studies. However, its value as a biomarker for the diagnosis and differential diagnosis of mental disorders is still controversial, and its change patterns among different mental disorders have not been compared. We conducted a network meta-analysis of BDNF levels in different psychiatric disorders including schizophrenia(SCZ), major depressive disorder(MDD), bipolar disorder(BD), panic disorder(PD), post-traumatic stress disorder(PTSD), obsessive-compulsive disorder(OCD), generalized anxiety disorder(GAD) and insomnia. Studies were identified by searching electronic databases through 31/05/2023. BDNF levels decreased in patients with BD, MDD, OCD, PD, SCZ compared with controls, while significantly increased in patients with PTSD. According to the network meta-analysis, BDNF levels were significantly decreased in MDD and SCZ compared with BD (−2.6, 95% CIs [−5.32 to −0.15] and − 2.68 95% CIs [−5.18 to −0.23] respectively). However, in the traditional meta-analysis, there was a trend towards lower BDNF levels in SCZ compared to BD, with no significant difference (SMD = −0.20, 95% CIs [−0.49 to 0.08]). In conclusion, abnormal BDNF levels have been found in psychiatric disorders, and the changes in peripheral BDNF levels in patients with psychiatric disorders were reconfirmed in this study, which suggests BDNF exhibits promising clinical utility and may hold diagnostic value in distinguishing between MDD and BD.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology